Answers are grounded in this paper and cite their sources.
Retrospective analysis demonstrates median survival of 19 months in glioblastoma patients, suggesting enhanced outcomes in specialized neuro-oncology care.
INTRODUCTION National statistics estimate the median survival of patients with O6-methylguanine-DNA methyltransferase (MGMT) unmethylated glioblastomas to be approximately 12 months. However, institutions with multidisciplinary neuro-oncology expertise may have improved survival. We aimed to evaluate the median survival of patients with MGMT unmethylated glioblastomas treated at a center with neuro-oncology specialization. We also characterized the molecular features of long-term survivors (≥36 months) who received standard of care with the Stupp protocol. METHODS We conducted a retrospective analysis of an IRB-approved database from 2020-2024 to determine the median survival of patients with IDH -wt MGMT unmethylated glioblastomas who received treatment with the Stupp protocol. RESULTS A total of 25 glioblastoma patients met the inclusion criteria. The median survival of patients with MGMT unmethylated glioblastomas who underwent treatment with the Stupp protocol was 19 months. 28% had multifocal disease at presentation, with a median survival of 18 months, compared to a median survival of 22 months in patients with a single disease focus. 36% (9 patients) survived for at least 24 months. 24% (4 patients) survived at least 36 months, and were defined as long-term survivors. One patient continues to be alive and stable at 72 months from diagnosis. All long term survivors had a single focus of disease at presentation and underwent a gross total resection. Amongst these patients, 75% (3 patients) received gliadel wafer placement, while 50% (2 patients) had somatic NF1 mutations, and 50% (2 patients) had RB1 mutations. CONCLUSION The median survival of patients with MGMT unmethylated glioblastomas at multidisciplinary neuro-oncology centers exceeds national expectations, despite receiving the same standard of care treatment. The survival benefit is likely due to multiple factors, including access to advanced neurosurgical care, multidisciplinary tumor board discussions guiding meticulous treatment plans, judicious use of steroids, and better management of neurologic comorbidities.
No takes yet. Share an insight, caveat, or question.
Pickles et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: